Market News

Clients set to benefit immediately through "higher yields" and "improved potent handling".

Novel, plasmid-free manufacturing system reduces the cost of goods and improves AAV quality to enable development of safer gene therapies.

Countries in the GCC have been concentrating their efforts to develop and grow their healthcare and pharmaceutical sectors as an integral part of a ten-year vision to diversify the region’s economy and reduce its dependency on crude oil. While th...

Acquisition will add Trodelvy, a first-in-class antibody-drug conjugate approved to treat breast cancer.

Humanigen's proprietary monoclonal antibody may prevent and treat cytokine storm, which is believed to trigger the acute respiratory distress syndrome in severe cases of COVID-19.

The NevoLine Upstream platform has been designed to address the needs of gene therapy and vaccine innovators and CDMOs for robust and cost-effective upstream viral vectors manufacturing.

Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe.

Together, the companies will aim to put forward new research projects against infectious diseases and antimicrobial resistance, potentially creating new therapies and technologies.

After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040.

The transaction will further complement and expand Mylan's complex injectables offering and presence in hospitals.

The company is already constructing a digital platform for the pharmaceutical industry that will utilize IoT devices and blockchain technology to link temperature control and other logistics information end-to-end.

The partnership will focus on developing multiple ADCs using Catalent’s proprietary SMARTag site-specific bioconjugation technology.

Hybrid clinical trials leveraging safety-focused, direct-to-consumer logistical solutions are taking center stage, ensuring research continuity.

THESS dispenser is equipped with an identity-vigilance system and warns patients when they need to take their treatment and verifies it has been delivered in accordance with the prescribed dose

CPHI & P-MEC India and Global Business Reports are pleased to bring you the Gujarat Pharma 2020 report, sharing our view on the most attractive opportunities in the Indian pharma market. The report provides an outlook for the Gujarat region in India as...

Best-in-class automation, robotics and state-of-the-art touchless production lines that provide the cleanliness required for parenteral packaging containers.

Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19.

X 3 Tablet Press incorporates production capabilities and versatility traditionally limited to large-scale production machines.

Semglee available in vial and pen presentations at a 65% discounted list price, the lowest available for a long-acting insulin glargine on the market.

Ventofor Combi Fix delivered by the PowdAir Plus dry powder inhaler.

Bridgewest to develop the site into a full-service contract development and manufacturing organization.

Researchers have designed a simple, low-cost device for subcutaneous injection of viscous formulations.

Forbius's lead investigational asset, AVID200 holds promise as an effective and well-tolerated therapeutic in fibrotic diseases and immuno-oncology.

The CMO's new Chief Operating Officer will continue the company's operational response to COVID-19.

Global Pharma Insights speaks to Deepak Sapra, CEO of Active Pharmaceutical Ingredients and Services at Dr. Reddy's Laboratories, for his perspective on the current state of the Indian healthcare and pharmaceuticals sector

The company will prepare the Harmans facility to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing later this year.

The company will target working with small and medium biotechs who require a science-driven, rather than a volume-driven partner.

The transaction will allow Takeda to focus on five key business areas.

This chart from investment advisory firm, Virtue Capital Partners Ltd, provides an up-to-date snapshot of how the US and the UK compare in terms of their respective investment in anti-COVID 19 vaccines and drugs, providing useful data such as number of...

This milestone secures future production of CombiGene's CG01 drug candidate to treat drug-resistant focal epilepsy.

Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators.

One of India's fastest growing CDMOs goes "beyond the norm" to reinvent itself as a new generation global CDMO.

The transaction will enable Sanofi to expand and accelerate development of BTK inhibitors across multiple indications, including MS and other central nervous system diseases.

The instrument also tests ethanol and isopropanol concentrations to confirm product efficacy.

The free webinar investigates online training and how it can essentially optimize the tablet manufacturing process.

Atomwise technology removes the barriers of physical screening that have limited the success of traditional methods for small molecule drug discovery.

Details of new CPHI South East Asia Online Business Matchmaking Platform to be announced shortly.

The company is also scaling up its manufacturing capability with its partners — Lonza, Catalent and Rovi — should the vaccine get the green light.

The company has reserved one fill/finish line for the next 18 months to guarantee the supply of vaccines required to fight COVID-19 in the UK.

Customers in the region will have the opportunity to conduct laboratory-scale compression and coating trials, using automated coating equipment.

The extension will add a capacity of over 10 million doses per annum to the site.

New mid-scale microbial facility will support Servier with API for acute lymphoblastic leukemia therapies.

The company expects to manufacture the clinical-stage gene therapy product in its commercial-scale GMP manufacturing facilities.

Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.

The companies are set to manufacture globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

The transaction will enable the CDMO to offer plasmid production and end-to-end cell and gene therapy services.

The European Medicines Agency's human medicines committee (CHMP) has recommended the suspension of European marketing authorizations of generic medicines tested by Panexcell Clinical Laboratories at its site in Mumbai, India, citing irregularities in h...

The company will adapt its digital platform to digitize any COVID-19 antibody rapid test assay and embed this within an app available on smartphones and tablets.

The event organizers are working on preparing bespoke digital product offerings to help the market continue to meet, do business and exchange ideas later this year.

The $30 million investment will enable the site to handle large-molecule programs, with additional capacity for small molecule dosage form development.

The data generated through the partnership will help biopharma companies to develop robust manufacturing processes and minimize challenges during scale-up and commercialization.

Acryl-EZE formulations provide significant time savings and targeted drug delivery.

Data on the first clinical use of lenzilumab in patients with severe COVID-19 pneumonia suggest promising results.

Watson-Marlow's new Certa Plus sinusoidal pump provides a sustainable solution for shear sensitive, viscous pharmaceutical products.

Sterile transfer solutions without compromising operational efficiency.

Junshi Biosciences cites Lonza’s GS Xceed gene expression system as a critical enabler for the program.

The company is also involved in projects that aim to enable population-level screening for the current coronavirus.

Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy.

The center will host a new BioReliance End-to-End Solutions GMP manufacturing facility offering CDMO services to customers in China and Asia-Pacific.

The agreement is aimed at helping to reduce essential drug shortages in the US

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Companies agree that the key to tackling drug development complexity is collaboration.

The transaction will more than double Croda’s R&D capability in drug delivery.

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

SeaGel offers drug and dietary supplement manufacturers an animal-free and sustainable alternative to traditional soft capsules.

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

The prefilled pen supports more convenient self-administration for patients with chronic type 2 inflammatory diseases.

Luxembourg, 28 May 2020 -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agr...

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

As Bill Gates had correctly predicted in 2015, the greatest threat to humanity was not nuclear missiles, but microbes.

Novel platform initially focussed on high-resolution industrial-scale processing of therapeutic mRNA.

Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

The cost-effective capsules incorporate anti-tampering measures to ensure they comply with blinding regulations.

An aging population and high incidence of NCDs is continuing to drive the demand for healthcare in Thailand, where 20% of the population is aged 65 or over. Our CPHI South East Asia webinar examines the challenges associated with dosage form design for...

Webinar will help manufacturers to harness the advantages of using real-time analytics to enhance performance and reduce waste.

The collaboration will significantly increase the UK’s capacity to manufacture viral vectors vaccines as part of a national effort in response to COVID-19.

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

The collaboration with CGT Catapult will enable Achilles to increase its GMP manufacturing capacity to supply clinical trials of its novel T cell therapy products.

The CDMO produce drug substance at large scale for commercial manufacturing with the first 2 years valued at approximately $480 million.

The rush to find effective vaccines against the coronavirus is only one part of the story. How is the pharmaceutical industry addressing the difficult issue of ensuring there will be enough manufacturing capacity to roll them out on a global scale?

Global Pharma Insights speaks to Stefan Schmidinger, Partner at Kemiex AG, on how its trade platform is bringing efficiency to a fragmented and regulated market and how traders of APIs are slowly embracing the digital revolution

The Boulder, Colorado, USA facility will increase global capacity and extend manufacturing scale.

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

US TEC will support biopharma drug development throughout the lifecycle, helping them overcome the challenges of the container-closure system.

Vaxxas announces Merck (known as MSD outside the US and Canada) milestone and Harro Höfliger manufacturing alliance.

The licence will allow the company to perform EU clinical release for its European customers and drug developers.

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Reducing dependence on China would increase production costs for generic drug makers, analysts say

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

CDMO is contracted to produce multiple clinical batches from German facility

Voluntary licensing deals allow firms to distribute drug recently granted FDA EUA to treat patients with COVID-19 in 127 countries

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Biotech in discussions with pharmaceutical and chemical manufacturers on how to broaden supply of antiviral that last week received an emergency use authorization for treatment of COVID-19 from the FDA

The contract packaging company has plans to install new equipment for the company’s blister and bottle lines, vial labelling, stability chambers and cold storage capacity.

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

By bringing tabletting knowledge to home offices and desk tops, the company encourages its customer to stay safe and stay skilled.

The new business unit will focus on existing automated biomanufacturing products, as well as launching new technologies.

The system has the potential to revolutionise the turnaround time for the assessment of suspected UTIs and reduce the use of antibiotics.

The addition of various laboratory and bioprocessing technologies will support customers to develop biotech medicines and vaccines.

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Human plasma-derived product will be developed and manufactured utilizing Kamada’s proprietary IgG platform technology

The CPO has immediate plans to expand its automated packaging capabilities, including for injectable products.

The acquisition will strengthen Wasdell’s capabilities and product offerings, including 100% recyclable and biodegradable options, in the medical device sector.

Syntegon's new coater series can handle tablets with highly potent active ingredients.

CDMO to supply drug substance manufacturing services and reserve capacity for possible commercial production next year